4.66
0.17 (3.67%)
| Previous Close | 4.50 |
| Open | 4.54 |
| Volume | 2,005,487 |
| Avg. Volume (3M) | 2,513,733 |
| Market Cap | 584,884,288 |
| Price / Sales | 11.46 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2026 |
| Profit Margin | -100.02% |
| Operating Margin (TTM) | -222.08% |
| Diluted EPS (TTM) | -0.580 |
| Quarterly Revenue Growth (YOY) | -27.70% |
| Current Ratio (MRQ) | 4.87 |
| Operating Cash Flow (TTM) | -48.77 M |
| Levered Free Cash Flow (TTM) | -20.21 M |
| Return on Assets (TTM) | -22.21% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Bullish |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Bullish | |
| Stock | Aquestive Therapeutics, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | -3.0 |
| Price Volatility | 1.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 0.72 |
|
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 5.62% |
| % Held by Institutions | 48.90% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Bratton Capital Management, L.P. | 30 Jun 2026 | 9,810,958 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BARBER DANIEL | - | 4.29 | -25,000 | -107,250 |
| Aggregate Net Quantity | -25,000 | |||
| Aggregate Net Value ($) | -107,250 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 4.29 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| BARBER DANIEL | Officer | 17 Aug 2026 | Sell (-) | 25,000 | 4.29 | 107,250 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |